AcuCort’s medicinal product receives renewed marketing authorisation from the Swedish Medical Products Agency

The pharmaceutical company AcuCort has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely.

AcuCort applied for and was granted marketing authorisation for its medicinal product in 2020. That authorisation was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation.

"Receiving renewed approval is an important mark of quality for AcuCort as we expand into more markets in Europe and further into the US," says AcuCort’s CEO Jonas Jönmark.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: [email protected]

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.